中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (1): 65-73.doi: 10.4103/1673-5374.314289

• 综述:退行性病与再生 • 上一篇    下一篇

肌萎缩性侧索硬化症的上下运动神经元受累及其对疾病预后的影响

  

  • 出版日期:2022-01-05 发布日期:2021-09-18

Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis

Maria N. Zakharova*, Anna A. Abramova   

  1. Research Center of Neurology, Moscow, Russia
  • Online:2022-01-05 Published:2021-09-18
  • Contact: Maria N. Zakharova, PhD, zakharova@neurology.ru.

摘要:

Neural Regen Res:上下运动神经元影响肌萎缩侧索硬化症表型和预后

肌萎缩侧索硬化症是一种致命的神经退行性疾病,其特征是进行性肌肉萎缩,呼吸和吞咽困难,导致患者在发病后25年内死亡。在肌萎缩侧索硬化症中,皮质脊髓束的上、下运动神经元都参与了神经退行性变的过程,导致了疾病的临床异质性。临床表型对肌萎缩侧索硬化症的发展模式和发生率以及总体生存预后有很大影响。在肌萎缩侧索硬化症的临床试验中,为了研究药物对疾病特殊表现的影响,建立更多的同质性患者群体是一个具有挑战性的问题。由于肌萎缩侧索硬化症的发病率较低,因此开展多中心试验需要某些标准化的疾病诊断和分期方法。前期研究认为肌萎缩侧索硬化通常开始于一个肢体的局部,然后蔓延到对侧肢体和邻近的解剖区域。大约20-30%的肌萎缩侧索硬化症患者有延髓发作,首先是说话和吞咽困难。尽管骨骼肌逐渐变弱,但直到疾病的最新阶段,动眼神经和括约肌仍然相对完整。

来自俄罗斯医学科学院的Maria N. Zakharova团队认为解决肌萎缩侧索硬化症临床试验中的疾病异质性可以引导研究设计,以评估特定患者亚组的药物疗效。每一个可能对疾病的临床表现和进一步病程产生影响的因素都应该考虑在内,因为它为疾病异质性和对相同治疗干预的不均匀反应提供了基础。在疾病的临床表现中,上运动神经元和下运动神经元信号的干扰产生了疾病独特的时空模式。肌萎缩侧索硬化症研究的主要目的是通过临床检查和所有可获得的仪器方法来全面了解其病理生理学,从而推测哪种治疗药物对患者最有利。如果我们的目标是在短期内获得更一致的研究结果,那么将神经生理学和神经影像学技术纳入肌萎缩侧索硬化症即将进行的临床试验是不可避免的。新的生物标志物可能改善肌萎缩侧索硬化症临床试验中现有的研究设计,并提供肌萎缩侧索硬化症神经退行性变病理生理学方面的见解。

文章在《中国神经再生研究(英文版)》杂志2022 1 1 期发表。

https://orcid.org/0000-0002-1072-9968 (Maria N. Zakharova); https://orcid.org/0000-0002-7960-1006 (Anna A. Abramova)

Abstract: Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive muscle wasting, breathing and swallowing difficulties resulting in patient’s death in two to five years after disease onset. In amyotrophic lateral sclerosis, both upper and lower motor neurons of the corticospinal tracts are involved in the process of neurodegeneration, accounting for great clinical heterogeneity of the disease. Clinical phenotype has great impact on the pattern and rate of amyotrophic lateral sclerosis progression and overall survival prognosis. Creating more homogenous patient groups in order to study the effects of drug agents on specific manifestations of the disease is a challenging issue in amyotrophic lateral sclerosis clinical trials. Since amyotrophic lateral sclerosis has low incidence rates, conduction of multicenter trials requires certain standardized approaches to disease diagnosis and staging. This review focuses on the current approaches in amyotrophic lateral sclerosis classification and staging system based on clinical examination and additional instrumental methods, highlighting the role of upper and lower motor neuron involvement in different phenotypes of the disease. We demonstrate that both clinical and instrumental findings can be useful in evaluating severity of upper motor neuron and lower motor neuron involvement and predicting the following course of the disease. Addressing disease heterogeneity in amyotrophic lateral sclerosis clinical trials could lead to study designs that will assess drug efficacy in specific patient groups, based on the disease pathophysiology and spatiotemporal pattern. Although clinical evaluation can be a sufficient screening method for dividing amyotrophic lateral sclerosis patients into clinical subgroups, we provide proof that instrumental studies could provide valuable insights in the disease pathology.

Key words: amyotrophic lateral sclerosis, biomarkers of progression, classification, diagnostic biomarkers, disease heterogeneity, electrodiagnostic medicine, electromyography, motor neuron disease, neuroimaging